Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404401 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy
A Phase 3 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT03404401 is a Phase 3 study that has completed, run by Braintree Laboratories. The registered enrollment target is 620 participants.
The verdict
NCT03404401, a Phase 3 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of BLI4700 bowel preparation to an FDA-approved bowel preparation as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.
Interventions
- DRUG BLI4700
- DRUG Polyethylene glycol bowel preparation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404401
The ClinicalTrials.gov registry entry for NCT03404401 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BLI4700 is the first listed.
NCT03404401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404401 about?
NCT03404401 is a clinical study titled "A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy". The objective of this study is to compare the safety and efficacy of BLI4700 bowel preparation to an FDA-approved bowel preparation as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.
What is the current status of trial NCT03404401?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2018-01-11. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT03404401?
The interventions under investigation include: BLI4700 (DRUG), Polyethylene glycol bowel preparation (DRUG).
Who is sponsoring clinical trial NCT03404401?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.